We look forward to more molecules from our programs reaching the clinic over time, and we will continue to report on these progressions to the clinic on a quarterly basis. In Q4 2023, we saw three new molecules advance to the clinic for a cumulative total of 13 molecules to have reached the clinic. Two undisclosed molecules from partner-initiated discovery in animal health were advanced into clinical field studies, and Arsenal Bio received an IND authorization for AB2100. AB2100 is an antibody with an indication in oncology that was derived by Arsenal Bio from a Trianni Mouse under a license from AbCellera.